Multinational drug companies such as Johnson and Johnson, Novartis and Pfizer have the fastest annual salary

Johnson and Johnson CEO Alex GorskyChief Executive Officer Alex Gorsky earned a total salary of $25.37 million in 2019, an increase of nearly $5 million over 2018, largely due to the increased value of pension benefitspublic release, Gorsuch's base salary was $1.65 million, the same as the previous year, but his stock and options awards were slightly lower than the previous year, while cash incentive pay increased slightly to $3.69 millionGorsuch also received a $9.96 million stock award and $4.05 million in options, both of which were slightly lower than in 2018The total amount of other subsidies was $243,000Johnson and Johnson Pharmaceuticals achieved sales of $42.198 billion in fiscal 2019, up 3.6% YoYAmong them, the annual sales of autoimmune drugs reached US$13.950 billion, up 6.33% YoY, and sales of oncology drugs reached US$10.692 billion, up 8.61% YoYInflixisi, Golimu, Usno, Daremu, Ibtini, etcare the main drivers of growthBut at the same time, strong survivors in 2019 are being challenged by lawsuits over opioids and baby powder productsLilly CEO David RicksLilly CEO David Ricks received a total compensation of $21.28 million in 2019, up 23.5 percent from $17.23 million in 2018's proxy filings show that Ricks' base salary was $1.4 million in 2018 and that his non-equity incentive pay actually fell from $3.63 million to $2.92 millionBut his stock awards rose 15 percent to $12.22 million, his pension was worth $4.66 million, and there was $84,000 in other compensationRicks has been Lilly's CEO since early 2017, undergoing a massive restructuring to cut costs and focus on new drug developmentAccording to industry analysts, 95 per cent of Lilly's drugs were old five years ago, but by the end of 2019 the proportion of older drugs had fallen to 51 per cent2019, Lilly acquired Loxoy Oncologford for $8 billion to expand its oncology pipeline, securing the broad-spectrum cancer drug larotrectinib and the thyroid cancer drug selperticinib, which treats RET-altering, which went on sale in 2018 and has been qualified for FDA priority review In 2019, Lilly's severe hypoglycemia non-injectable emergency therapy Baqsimi powder and migraine drug Reyvow were approved for sale AstraZeneca chief executive Pascal Soriot , according to AstraZeneca's earnings report, chief executive Pascal Soriot received a total compensation of 14.3 million pounds ($18.54 million) in 2019, up about 26 percent from 11.36 million pounds in 2018 of Soriot's total compensation, which is a base salary of 1.8 million pounds, an end-of-year bonus of 1.9 million pounds, a long-term incentive and dividend equivalent of 6.3 million pounds, and a share appreciation and dividend of 4.3 million pounds , Soriot was one of three pharmaceutical CEOs to make the list of the world's top 100 CEOs in the 2019 Harvard Business Review Under Soriot's leadership as CEO of AstraZeneca since October 2012, AstraZeneca has focused on its product pipeline, particularly in oncology, with a focus on its portfolio and strategic development in emerging markets, including China AstraZeneca will divide its oncology business into separate divisions in early 2019, consolidating cardiovascular, respiratory diseases, diabetes and other business segments into biopharmaceuticals In 2019, sales of anti-cancer drugs such as Teresa, Lipdro, PD-L1 inhibitor infyl AstraZeneca's long-term investment in the Chinese market has also paid off, with annual revenue of $4.88 billion in 2019, contributing to more than a fifth of AstraZeneca's global revenue Pfizer CEO Albert Bourla
Albert Bourla has officially replaced Ian Read as Pfizer's new helmsman from January 1, 2019 His total compensation in 2019 was $17.9 million, an 82% increase over his previous company's total annual compensation under Bourla's leadership in 2019, Pfizer's performance was also better Pfizer reported revenue of $52.4 billion in 2019, exceeding the board's $51.7 billion performance target, and the company's cash flow reached $12.9 billion, above the $11.6 billion benchmark, and its diluted earnings per share of $3.00, above its target of $2.81 Bourla received a $3.63 million incentive award in 2019 because of Pfizer's strong operating performance Bourla has also made a number of achievements in his first year as Pfizer's CEO, focusing on the innovative drug business Under his leadership, Pfizer completed its early merger with GSK's consumer health business into a joint venture, creating the world's largest over-the-counter deal In early 2020, Bourla told jPM health conference that the joint venture plans to launch an IPO in three to four years In addition, Pfizer's generic brand and mature pharmaceutical business unit, Puqiang, merged with Mylan at the end of July 2019 to form the world's largest generic pharmaceutical company On June 17th Pfizer announced its $11.4 billion acquisition of Array BioPharma to further develop the market for oncology drugs Bourla's strategy for the future, he said, adding to his investment in research and development in 2020 Pfizer also expects 25 products to be approved by 2022, covering rare diseases, oncology, anti-infective drugs and other areas, 15 of which have the potential to become a bombshell Roche CHIEF Executive Severin Schwan Roche CEO Severin Schwan's total compensation for 2019 was essentially the same as the previous year, down about 2 percent to 11.5 million Swiss francs ($12.2 million) Roche reported revenue of $65.12 billion in 2019, up 9% year-on-year, and performance was better overall Amvetin, Herselitin and Merlot remain the "troika" of sales, with sales in the Chinese market-driven international market up 11 per cent year-on-year Overall performance is better , Schwan's pay changes are actually related to changes in Roche's performance-based reward model that link Schwan's compensation to long-term growth in the company's performance rather than short-term stock performance Schwan's base salary is still 4 million Swiss francs ($4.3 million), unchanged from the previous year, but his PSP bonus fell from 1.49 million Swiss francs to zero The company was not paid as a result of the company's board's remuneration committee's decision to discontinue the issuance of a new performance sharing program (PSP) to board members and executive committee members from the end of 2018 According to Roche's annual report, Roche's PSP incentive program began in 2002 on a three-year basis, based on a comparison of Roche's overall shareholder returns with the overall shareholder returns of 15 of its peers The end of 2020 is the final three-year cycle, at which time the remuneration committee will determine the circumstances of the decision on payment Novartis chief executive Vas Narasimhan Novartis CEO Vas Narasimhan received a total compensation of 10.62 million Swiss francs ($11.37 million) in 2019, and Novartis increased the value of its compensation plan by 59 percent According to public information, the median salary of total remuneration is CHF 1.65 million, pension insurance and other benefits is approximately CHF 330,000, and the full-year incentive for 2019 is CHF 4.02 million, as well as other forms of compensation such as long-term equity awards Vas Narasimhan has been Ceo of Novartis since February 1, 2018 Under his leadership, Kymriah, the world's first CAR-T therapy, was approved for the market Novartis has faced challenges in recent years from patent expirations and generic competition, with core varieties Imatinib expiring its patents to reach $14.37 billion in 2019, but growing by only 7%, while eye product Thunderball is also challenged by competition November 2019, Novartis announced its acquisition of U.S biotech pharmaceutical company Medicines for a total of about $9.7 billion, expanding its presence in cardiovascular disease treatment, and acquiring Novartis to acquire the cholesterol-lowering drug Inclisiran, which is expected to be an important driver of Novartis' future medium- and long-term earnings growth For the Chinese market, Vas Narasimhan has publicly stated that it expects to submit 50 new drug applications in China in the next five years emma Walmsley, GSK chief executive
After three years as CEO executive Emma Walmsley, GSK boss Emma Walmsley's pay levels have finally moved away from the industry's "bottom" level In 2019, Emma Walmsley will receive a total salary of 8.4 million pounds ($10.85 million), and public information reveals that her base salary will rise by 8 per cent to about $1.55 million in 2020 2019, GSK achieved revenue of about $43.75 billion, up 10% year-on-year, with a relatively bright growth rate among multinational pharmaceutical companies under her leadership, in early 2019, GSK completed a $5.1 billion deal to expand the oncology pipeline in its $5.1 billion acquisition of Tesaro, a U.S cancer drug company, and acquired the listed PARP inhibitor Zejula (niraparib), which was approved for ovarian cancer treatment, and PD-1 mono-anti-dolimamarb In August, GSK also completed a joint venture with Pfizer's consumer health care business GSK is divesting assets as well as acquiring consolidation In June 2019, GSK plans to sell drug sales rights and Physiogel skincare products in the Latin American market, raising about $1.3 billion, and in October sold the rabies vaccine Rabipur and cerebellum encephalitis vaccine Encepur for about $1.1 billion On February 24th GSK sold its 15 consumer health brands, mainly in European countries, to German generic drugmaker Stard for about 300 million euros and revealed plans to spin off some of its antibiotic business in 2020 Emma Walmsley told the JPM Health Conference at the end of 2019 that GSK will launch five new products in 2020 covering diseases such as cancer, AIDS and kidney disease, as well as expanding the adaptation of existing drugs such as the ovarian cancer drug Zejula and the asthma drug Trelegy original title: Johnson, Johnson, AZ, Pfizer and other multinational drug companies CEO annual salary match, who is the fastest growth? Who is the highest paid?